Medicines (MDCO) 10-Q2004 Q2 Quarterly report

Filed: 6 Aug 04, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Good

New words: absorb, Adest, aimed, Angiox, aspect, attempting, avoid, bear, beneficial, brought, CHMP, choose, consent, constructive, convenient, criminal, decide, deciding, declared, desirable, desired, discourage, discretion, effort, expend, expenditure, export, formation, gain, gaining, GMP, governmental, half, Hospira, inability, inconclusive, inconvenient, inspect, inspection, interruption, launch, length, letter, member, narrow, narrowed, negative, nonexclusive, nonrenewal, novelty, opposition, outcome, policy, preclinical, proxy, publicly, quality, recall, refusal, refuse, resist, revocation, seizure, service, side, site, sought, spent, stage, stockholder, stop, strict, structure, suit, suspension, sustain, takeover, team, threatened, type, unannounced, unanticipated, undesirable, unexpected, valid, view, volatile, volatility, warning, withdrawal, world, written

Removed: accelerated, cGMP, check, David, domestic, Employer, enjoined, fee, filer, Identification, impose, liable, mark, marketed, par, revalued, shorter, show, Stack, stringent, telephone, unfavorably, unvested, WASHINGTON, withdrawn

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

MDCO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of The Medicines Company (the “Company”) for the period ended June 30, 2004 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven H. Koehler, Senior Vice President and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

		By:	/s/ Steven H. Koehler

Dated:	August 6, 2004	Steven H. Koehler
		Senior Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to The Medicines Company and will be retained by The Medicines Company and furnished to the SEC or its staff upon request

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.